# Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

> **NCT00923936** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Sarcoma, Kaposi

## Interventions

- **DRUG:** Liposomal Doxorubicin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00923936
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-23
- **Primary completion:** 2015-05-13
- **Final completion:** 2017-11-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923936, "Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00923936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*